Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clearance of 25-hydroxyvitamin D in CKD
NCT02937350Phase 1Completed
- Sponsor
- University of Washington
- Start
- Mar 2017
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of d6-25-hydroxyvitamin D3 in chronic kidney disease (CKD), sponsored by University of Washington. Primary endpoint: Metabolic Clearance of D6-25(OH)D3 at 8 weeks. Started Mar 2017; status: completed.
02
Drugs
d6-25-hydroxyvitamin D3
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT02937350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02937350.